XML 59 R42.htm IDEA: XBRL DOCUMENT v3.24.0.1
Share-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Components of Share-Based Compensation Expense by Type of Award The following table lists the components of share-based compensation expense by type of award.
 Years Ended December 31,
 202320222021
Restricted stock$2,237 $3,635 $2,166 
Performance share units570 602 797 
Stock options14 140 253 
Share-based compensation expense$2,821 $4,377 $3,216 
Reconciliation of Restricted Stock Option Activity
The following table presents the status of unvested restricted stock awards as of December 31, 2023 and changes during the year then ended.
Nonvested
Restricted
Shares		Weighted Average Grant-Date
Fair Value
Unvested at January 1, 20231,038 $4.03 
Granted3,782 1.37 
Vested(1,146)3.65 
Forfeited(269)1.43 
Unvested at December 31, 20233,405 $1.41 
During the year ended December 31, 2023, we granted 1,952,000 shares of restricted stock to non-executive directors, officers and certain other employees under the Incentive Plans. These shares vest pro-rata generally over three years for employees and over one year for non-executive directors. During the year ended December 31, 2023, we granted 1,830,000 shares of restricted stock, outside of the Incentive Plans, to new executive officers as inducement awards, which vest pro-rata over five years.
Schedule of Stock Options Roll Forward The following table presents stock option activity for the year ended December 31, 2023.
Number of OptionsWeighted-Average
Exercise Price		Weighted-Average Remaining Contractual TermAggregate
Intrinsic
Value		 
Outstanding at January 1, 2023538 $12.63 
Expired(242)10.39 
Outstanding and exercisable at December 31, 2023296 $14.46 2.9 years$— (1)
_______________________________
(1)The aggregate intrinsic value is the sum of intrinsic values for each exercisable individual option grant. The intrinsic value is the amount by which the closing market price of our stock at December 31, 2023, was greater than the exercise price of any individual option grant